

**Super-iODN- class I/II hybrid. Potential TLR7 and TLR8 signaling Inhibitor (Antigen Grade)**

☐ **Cat.SIODN-1**

Super-iODN- class I/II hybrid.-Potential TLR7 and TLR8 signaling Inhibitor (Antigen Grade)

**Size: 1 mg**

CpG oligodeoxynucleotides (or CpG ODN) are short single-stranded synthetic DNA molecules that contain an unmethylated CG (Cytosine–guanine) di nucleotide in a specific base sequence (CpG motifs). The p refer to the phosphodiester backbone. These CpG motifs are not seen in eukaryotic DNA are considered pathogen-associated molecular patterns (PAMPs). The CpG PAMP is recognized by (TLR9). 3 types of, stimulatory ODNs have been identified based upon immunostimulatory activities.

Several groups have studied the sequence requirements, specificity, signaling pathways and kinetics of the TLR (Toll-like receptor) 9 suppression by 'inhibitory DNA motifs', which led to a revised classification of inhibitory ODNs.

Class I: G-stretch ODNs: TLR9-specific competitors, some iODNs may also affect TLR7 and TLR8 signaling

Class II: ODNs with telomeric repeats: TLR-independent inhibitors of STAT signaling (cellular uptake via an "ODN receptor"?)

Class III: Inhibitors of DNA uptake in a sequence independent manner  
Class IV: Long phosphorothioate ODNs as direct competitors of TLR9 signaling in a sequence independent manner

**Core iODN** is an Inhibitory iODN. It contains a particularly potent sequence of an inhibitory ODN for *in vivo* use in rodents based on class I and class II sequences to combine inhibitory activity on TLRs and STAT signaling.

**Cat. #: CIODN-1**

<b>Sequence</b>	5'-cctcaataggggtgagggg-3' (18mer)
<b>Mol. Wt</b>	4920
<b>Purity</b>	≥95%
<b>Form and storage</b>	Powder. After reconstitution, Store at -20C up to 1 year
<b>Shipping</b>	Shipped at 4° C
<b>Endotoxin</b>	<0.002 EU/μg
<b>Solubility</b>	water, PBS or other buffers (up to 5 mg/ml)

**Notes:**

- 1) Bases in capital are phosphodiester and those in lower case are phosphorothioate. Palindromic sequences are underlined.
- 2) Negative control Contains GpC nucleotides instead of CpG.

**General references:** Krieg,A.M(1995).Nature, 374(6522):546-9..Ballaz ZK(2001) 167(9). Bauer, (2001).PNAS.98(16):9237-42. Stunz LL(2002) Eur J Immunol.(5):1212-22.

*\*for in vitro research only\**

**Related Items**

Catalog#	ProdDescription
ODN006-1	ODNBW006 Type B CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' end
ODN1668-1	ODN 1668-Type B murine TLR9 Agonist-Antigen grade
ODN1668-1NCODN 1668-	Type B murine TLR9 Agonist (Negative Control), antigen grade
ODN1826-1	ODN 1826- Type B murine TLR9 Agonist-antigen grade
ODN2006-1	ODN 2006 -Type B-human TLR9 agonist-antigen grade
ODN2007-1	ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade
ODN2216-1	ODN 2216-Type A human TLR9 Agonist.-antigen grade
ODN2395-5	ODN 2395-Type C human/murine TLR9 agonist-antigen grade
ODN4084F-1	ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade
ODN4084F-5	ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade
ODNTT-1NC	ODN TTAGGG-Class G Human-TLR 9 Antagonist, antigen grade
SIODN-1	Inhibitory iODN- class I/II hybrid, may also affect TLR7 and TLR8 signaling.

**SIODN-1**

rev140220N

130215P